You must be logged in and own this session in order to
1/13/21 9:34 am
Good day sir.
Please how did your team take care of ADE antibody dependent enhancement, to ensure it is negated as effect from this vaccine ?
Was BNT162b2 mRNA designed to take care of mutations that led to Sarscov-2 mutants such as B.1.1.7 UK mutant and 501.V2 mutant ?
The key muttion in 501.V2 South African mutant presents a key mutation in spikenororein called E484K. This mutation is reputed to reduce antibody recognition.This enhances progression of diseases, create windows for possible rapid spread and can be a source of concern to developed vaccines.
Has this BNT162b2 mRNA been designed to neutralize this problem and shrug it off to enhance long lasting protection ? Or do we have a challenge in our hands that requires us LL to wait for some months and see how these current 3 vaccines from Pfizer-BioN Tech, Moderna and Astra Zeneca-Oxford University cope ?
Good luck, thank you and I comments your efforts at BioN Tech.
Your efforts at BioN Tech is commendble.
Warm regards sir.
Walden University MN US